Hit and Run: Bilateral Massive Intraocular Lymphomatous Infiltration after CAR-T Therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36952531/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusion: Atypical intraocular metastasis of DLBCL may occur following CAR-T therapy and may indicate secondary changes in immunosurveillance within immune-privileged sites such as the eye.
Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: a network meta-analysis of 20 RCTs - Annals of Hematology
Source : https://link.springer.com/article/10.1007/s00277-023-05161-1
Because of lacking of head-to-head comparison among polatuzumab (Pola) vedotin and other novel agents for untreated diffuse large B-cell lymphoma (DLBCL), the optimal option remains undefined. We searched twelve relevant...
Conclusions/Relevance: The PFS advantage with Pola-R-CHP over other regimens might be confined to those patients of ABC-type DLBCL.
Prognostic value of metabolic tumor volume of extranodal involvement in diffuse large B cell lymphoma - Annals of Hematology
Source : https://link.springer.com/article/10.1007/s00277-023-05165-x
Extranodal involvement predicts poor outcomes of diffuse large B cell lymphoma (DLBCL), but the impact of the metabolic tumor burden (MTV) of extranodal sites using positron emission tomography has not...
Conclusions/Relevance: When both the number and MTV of extranodal involvements were used as covariables, extranodal MTV remained a significant predictor of OS (HR 1.070, 95%CI 1.017–1.127, P = 0.009), but the number of extranodal sites did not. Extranodal MTV potentially had a more significant role on prognosis than nodal MTV. When considering prognostic impacts, the MTV of extranodal involvement is significantly more important than the number.
Prognostic value of cross-lineage expression of the myeloid-associated antigens CD13 and CD33 in adult B-lymphoblastic leukemia: A large real-world study of 1005 patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36951610/
In real-world practice, CD13/CD33 expression can predict the risk of MRD in patients without TKI experience, but has no adverse effect on the prognosis of adult B-ALL patients. Incorporating CD13/CD33...
Conclusions: In real-world practice, CD13/CD33 expression can predict the risk of MRD in patients without TKI experience, but has no adverse effect on the prognosis of adult B-ALL patients. Incorporating CD13/CD33 into the standard antibody panels of B-ALL diagnosis and MRD measurements can help predict relapse risk and decisions on therapy options.
Drug-tolerant persister B-cell precursor acute lymphoblastic leukemia cells
Source : https://www.biorxiv.org/content/10.1101/2023.02.28.530540v1
Reduced responsiveness of precursor B-acute lymphoblastic leukemia (BCP-ALL) to chemotherapy can be inferred when leukemia cells persist after 28 days of initial treatment. Survival of these long-term persister (LTP) /...
Conclusions/Relevance: Although the drug transporter ABCC1/MRP1 is not overexpressed in BCP-ALL, a functional gene was needed for DTP cells to survive treatment with vincristine. This suggests that addition of possible ABCC1 inhibitors during induction therapy could provide benefit in eradication of minimal residual disease in patients treated with a chemotherapy regimen that includes vincristine.
Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36929591/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Relevance: CD5-positive (CD5+) DLBCL is characterized by aggressive clinical characteristics and frequent CNS relapse. In 2020, we reported the results of the primary analysis of a phase 2 study of dose-adjusted (DA)-EPOCH-R combined with high-dose (HD)-MTX (DA-EPOCH-R/HD-MTX) (PEARL5 study) with a median follow-up of 3.1 years. In this letter, we report the results of our preplanned 5-year follow-up of this study.